Anthony C. J. Fernando - 08 Jun 2021 Form 4 Insider Report for ASENSUS SURGICAL, INC.

Role
President and CEO, Director
Signature
/s/ Joshua Weingard, as attorney in fact for Anthony Fernando
Issuer symbol
N/A
Transactions as of
08 Jun 2021
Net transactions value
-$1,602,204
Form type
4
Filing time
10 Jun 2021, 20:40:06 UTC
Next filing
07 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ASXC Common Stock Options Exercise $0 +550,000 +407% $0.000000 685,126 08 Jun 2021 Direct F1
transaction ASXC Common Stock Tax liability $828,514 -245,850 -36% $3.37* 439,276 08 Jun 2021 Direct F2
transaction ASXC Common Stock Sale $7,413 -2,112 -0.48% $3.51* 437,164 08 Jun 2021 Direct F3
transaction ASXC Common Stock Options Exercise $150,337 +183,338 +42% $0.8200 620,502 09 Jun 2021 Direct
transaction ASXC Common Stock Sale $568,348 -183,338 -30% $3.10* 437,164 09 Jun 2021 Direct F4
transaction ASXC Common Stock Sale $348,265 -112,344 -26% $3.10* 324,820 09 Jun 2021 Direct F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ASXC Restricted Stock Units Options Exercise $0 -550,000 -100% $0.000000* 0 08 Jun 2021 Common Stock 550,000 $0.000000 Direct F6, F7
transaction ASXC Stock Option Options Exercise $0 -183,338 -33% $0.000000 366,662 09 Jun 2021 Common Stock 183,338 $0.8200 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Lapse of forfeiture restrictions on one grant of restricted stock units ("RSUs") awarded on June 8, 2020.
F2 This transaction represents the payment of a tax liability on the lapse of forfeiture restrictions on a derivative security and acquisition of the underlying shares.
F3 The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.50 to $3.525 inclusive. The reporting person undertakes to provide to Asensus Surgical, Inc., any security holder of Asensus Surgical, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
F4 The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0 to $3.19 inclusive. The reporting person undertakes to provide to Asensus Surgical, Inc., any security holder of Asensus Surgical, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
F5 Prior to the transactions reported on this Form 4 the reporting person owned 135,126 shares of the Company's common stock. Following the vesting and sale transactions reported on this Form 4, the reporting person increased his ownership of the Company's common stock by approximately 190,000 shares. The reporting person also holds stock options to acquire 575,269 shares of common stock, of which approximately 31% are vested, and restricted stock units representing an additional 278,206 shares of common stock subject to forfeiture restrictions.
F6 Each RSU represents the right to receive one share of the Registrant's common stock.
F7 Lapse of forfeiture restrictions on the 550,000 RSUs from this grant made on June 8, 2020.